MA-ALLURION-TECH
Allurion Technologies , a pioneering leader in the development of innovative, scalable and trusted weight loss experiences, today announced new clinical data on the Elipse Balloon at ObesityWeek 2020. The Allurion Program features the Elipse Balloon, the world’s first and only procedureless weight loss device. The balloon is designed to remain in the stomach for 4 months and is paired with a Bluetooth® connected scale and Allurion smartphone app and a supervised nutritional program.
In Long-Term Efficacy of the Elipse Gastric Balloon System: An International Multicenter Study , Dr. Roberta Ienca and colleagues report on 509 patients who received the Elipse Balloon and were followed for one year. After 4 months of Elipse Balloon treatment patients achieved weight loss of 14.4 ± 7.7kg or 13.9 ± 6.4% of total body weight. At one-year follow-up, 95% of this weight loss was sustained.
In Sequential Elipse Balloon Treatment: 1-Year Weight Loss Results Approximates Bariatric Surgery Results , Dr. Roberta Ienca and colleagues report on 42 patients treated with sequential Elipse Balloons. Between one and five months following the passing of the first Elipse Balloon, a second balloon was placed. After 4 months, mean weight loss and percent total body weight loss were 14.7 ± 4.4kg and 14.4 ± 3.6%, respectively. The second balloon resulted in an additional 8.8 ± 5.7kg and 10.0 ± 6.5% weight loss, respectively. In total, sequential balloon treatment resulted in weight loss of 22.0 +/- 9.0kg or 22.8 +/- 8.8%, and a body mass index (BMI) decrease of 8.1kg/m2 from baseline.
“Both of these studies demonstrate the potential that the Allurion Program has in providing consumers with long-term and sustainable results,” said Dr. Shantanu Gaur, co-founder and CEO of Allurion. “Additionally, this data indicates that consumers can achieve life-changing results without needing to undergo surgery, endoscopy or anesthesia.”
“The Elipse Balloon provides my patients with a primary weight loss tool and an alternative to weight loss surgery,” said Dr. Alberto Pagan, Clinica CINIB, Palma de Mallorca, Spain. “These results underscore how the Allurion Program can deliver both short and long-term results that meet the expectations of my patients.”
“The clinical data presented at Obesity Week is reflective of the increasing demand for our product around the world,” said Benoit Chardon, Executive Vice President Commercial for Allurion. “We have tripled the number of patients treated in the past year and have created a reputation for clinical results that providers and patients can trust.”
About Allurion Technologies
Allurion Technologies is dedicated to helping people realize their full potential with innovative, scalable and trusted experiences. The company's flagship product, the Allurion Program, is a 360-degree weight loss experience featuring the Elipse Balloon, the world’s first and only swallowable, procedureless gastric balloon for weight loss. Learn more about the Elipse Balloon and Allurion online at www.allurion.com , on Facebook at www.fb.com/allurion or on Twitter @alluriontech .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201110005027/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial 3-axis accelerometer has high offset stability24.6.2025 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has introduced a 3-axis accelerometer for the industrial market that combines high offset stability over temperature and time, good linearity, low noise density, and excellent robustness. The SCA3400-D01 XYZ accelerometer is meant for use in industrial applications such as structural health monitoring (SHM), machine control, inertial measurement units, and construction tools and systems. This product will be exhibited at Sensors Converge 2025 to be held at the Santa Clara Convention Center (Booth #716), California from 24 to 26 June 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250623994075/en/ [Murata Manufacturing Co., Ltd.] Industrial 3-axis accelerometer The offset stability of an accelerometer refers to the consistency of its output when at rest, but subject to varying temperatures or the effects of aging. Ideally, this output should be zero, but i
Grid Dynamics Announces AI-Powered Engagement Model Enabling Accelerated Business Transformation for Fortune 1000 Enterprises23.6.2025 15:15:00 CEST | Press release
Key Takeaways: Grid Dynamics introduces an AI-powered engagement model for software delivery. This engagement model expands Grid Dynamics’ offerings by providing a fundamentally new way of delivering value—enabling clients to achieve superior outcomes by providing the next level of agility, quality, and accelerated time-to-market. The model is based on the Grid Dynamics AI-Native Development Framework (GAIN Development Framework)—a combination of proprietary processes, human capital, and an AI-Enabled Development Platform. This framework is designed specifically to support the scale and complexity of Fortune 1000 enterprises. Based on internal benchmarks, we expect this model to accelerate project delivery by achieving over 30% productivity improvements. Progressive credit-based pricing directly tied to performance and value is the basis of the new engagement model. Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (Grid Dynamics)—a prominent technology consulting and digital services provid
Live Biotherapeutics at a Crossroad: Novotech White Paper Outlines Opportunities and Early-Stage Challenges23.6.2025 14:05:00 CEST | Press release
As Live Biotherapeutic Products (LBPs) begin to transition from frontier science to clinical reality, Novotech, a leading global CRO and scientific advisory partner has published a new white paper examining the opportunities and challenges shaping this fast-evolving landscape of therapeutic class. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250623205345/en/ LBPs, which harness live microorganisms to restore or modulate human health, are being explored across a growing range of indications, from gastrointestinal and metabolic disorders to CNS and oncology. FDA approvals of Rebyota™ and Vowst™ have validated the category but for most biotech sponsors, the journey remains uncertain. According to Novotech’s analysis, over 90% of LBP assets are still in early development stages, and nearly one-third of all trials from 2020 to 2025 have been withdrawn or suspended due to regulatory, manufacturing, or design complexities. Highli
Sagemcom’s Net Zero Trajectory Approved by SBTi: Target Set for 204023.6.2025 14:00:00 CEST | Press release
Sagemcom Group has today reached a critical milestone in its climate strategy: its Net Zero carbon target for 2040—encompassing all activities and sites within the Group’s consolidated scope—has been officially validated by the Science Based Targets initiative (SBTi). This international endorsement attests to the scientific rigor of Sagemcom’s decarbonization strategy, aligned with the Paris Agreement’s ambition to limit global warming to 1.5°C. It strengthens the Group’s comprehensive climate roadmap, which is built on a significant reduction of greenhouse gas emissions across all scopes: By 2030: A 47% absolute reduction in Scope 1 and Scope 2 emissions (direct emissions and purchased energy), 100% renewable energy consumption across all Group sites, A 31% absolute reduction in Scope 3 emissions, including those related to the value chain, with no exclusion of any greenhouse gas categories. By 2040: Achievement of Net Zero, corresponding to a 90% absolute reduction in total Group emi
One, Two, Three-Peat: Mary Kay Inc. Named #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World for Three Years in a Row23.6.2025 14:00:00 CEST | Press release
Good things come in threes: iconic beauty brand and global entrepreneurship company Mary Kay Inc. has again been named the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World1 by Euromonitor International for the third consecutive year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250623000452/en/ Ryan Rogers, Chief Executive Officer of Mary Kay states: "Being named the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World by Euromonitor International three years in a row marks a grand slam achievement for Mary Kay. This repeated milestone reflects years of R&D and marketing efforts to create skin and beauty solutions that meet consumer needs and are loved the world-over. Above all, it demonstrates the transformative power of our Independent Beauty Consultants who are driving this success globally." (Photo Courtesy: Mary Kay Inc.) Euromonitor International is the foremost provider of globa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom